Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Other Working Capital Changes (2021 - 2025)

Verrica Pharmaceuticals has reported Other Working Capital Changes over the past 5 years, most recently at -$494000.0 for Q4 2025.

  • Quarterly results put Other Working Capital Changes at -$494000.0 for Q4 2025, down 135.72% from a year ago — trailing twelve months through Dec 2025 was $782000.0 (down 30.67% YoY), and the annual figure for FY2025 was $782000.0, down 30.67%.
  • Other Working Capital Changes for Q4 2025 was -$494000.0 at Verrica Pharmaceuticals, down from $1.4 million in the prior quarter.
  • Over the last five years, Other Working Capital Changes for VRCA hit a ceiling of $1.9 million in Q3 2023 and a floor of -$2.8 million in Q2 2023.
  • Median Other Working Capital Changes over the past 5 years was -$74000.0 (2023), compared with a mean of $32882.4.
  • Biggest five-year swings in Other Working Capital Changes: crashed 185.12% in 2023 and later skyrocketed 1822.97% in 2024.
  • Verrica Pharmaceuticals' Other Working Capital Changes stood at -$473000.0 in 2021, then surged by 265.75% to $784000.0 in 2022, then crashed by 46.43% to $420000.0 in 2023, then skyrocketed by 229.29% to $1.4 million in 2024, then crashed by 135.72% to -$494000.0 in 2025.
  • The last three reported values for Other Working Capital Changes were -$494000.0 (Q4 2025), $1.4 million (Q3 2025), and -$78000.0 (Q2 2025) per Business Quant data.